THE IMPACT OF PURINE DERIVATIVES THERAPY FOR PATIENTS WITH MEDICATION-RELATED OSTEONECROSIS OF THE JAW: PRELIMINARY RESULTS FROM A PILOT STUDY – THE SEQUEL

The pharmacological protocol using pentoxifylline and tocopherol (PENTO-E) seems to be a promoter according to some authors and is becoming a possible therapeutic proposal in the management of medication-related osteonecrosis of the jaw (MRONJ), though studies have shown its benefit in the management of osteoradionecrosis. The purine derivatives as is pentoxifylline aims to overcome the oxidative stress associated with the rebound effect by improving local circulation. In this study, the therapeutic approach based on the pharmacological association pentoxifylline and tocopherol showed a high cure rate, regardless of the stage of the disease. Thus, PENTO-E therapy could be a safe and effective additional strategy in the management of MRONJ.